IGF2BP2

Across TCGA pan-cancer cohorts, IGF2BP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGF2BP2 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IGF2BP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGF2BP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where IGF2BP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	32	view →
HNSC	DFS	Tertile	II,III,IV	0.889	0.663	.004	30	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	19	view →
LUAD	OS	Tertile	All	0.600	1.000	.009	11	view →
UCEC	DFS	Median	All	0.857	0.947	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IGF2BP2–CCRCC (DFS)

Open the CCRCC breakdown →